3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
35
Carcinoma, Hepatocellular
28
Stomach Neoplasms
12
Neoplasm Metastasis
12
Nasopharyngeal Carcinoma
11
Neoplasms
10
Esophageal Neoplasms
10
Melanoma
8
Esophageal Squamous Cell Carcinoma
8
Colorectal Neoplasms
8
Recurrence
7
Lung Neoplasms
7
Breast Neoplasms
7
Biliary Tract Neoplasms
7
Triple Negative Breast Neoplasms
6
Small Cell Lung Carcinoma
5
Rectal Neoplasms
5
Pancreatic Neoplasms
5
Head and Neck Neoplasms
5
Cholangiocarcinoma
5
Squamous Cell Carcinoma of Head and Neck
4
Locally Advanced Rectal Cancer
4
Colonic Neoplasms
4
Carcinoma, Renal Cell
4
Advanced NSCLC
4
Urinary Bladder Neoplasms
3
Sarcoma
3
Liver Neoplasms
3
Leukemia, Myeloid, Acute
3
Hyperthermia
3
Interventions
telitacicept
2
Prednisone
2
Blood Specimen Collection
2
thymoglobulin
1
remdesivir
1
prednylidene
1
fludarabine
1
deltacortene
1
carmustine, poliferprosan 20 drug combination
1
apremilast
1
Vitamin D
1
Valsartan
1
Telemedicine
1
Surveys and Questionnaires
1
Standard of Care
1
Specimen Handling
1
Pyridostigmine Bromide
1
Practice Guidelines as Topic
1
Population Groups
1
Peripheral Blood Stem Cell Transplantation
1
Nivolumab
1
Mycophenolic Acid
1
Music Therapy
1
Methods
1
Melphalan
1
Mastectomy, Segmental
1
Mammaplasty
1
Interviews as Topic
1
Infliximab
1
Immunotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Autoimmune Diseases
×
Immune Checkpoint Inhibitors
×
Clear all
NCT03492242
2019-09-26
CHIMeRA
Groupe Hospitalier Pitie-Salpetriere
Completed
1,000 enrolled